**Core Concept**
Abciximab is a monoclonal antibody that selectively inhibits the glycoprotein IIb/IIIa receptor on platelets, preventing platelet aggregation and fibrinogen binding.

**Why the Correct Answer is Right**
Abciximab is a potent antiplatelet agent used in acute coronary syndromes, including myocardial infarction and unstable angina. By blocking the glycoprotein IIb/IIIa receptor, abciximab inhibits the final common pathway of platelet aggregation, thereby reducing the risk of thrombotic complications. This mechanism of action is distinct from aspirin and heparin, which act on different pathways to inhibit platelet aggregation.

**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect because abciximab is not a glycoprotein IV inhibitor; it specifically targets the glycoprotein IIb/IIIa receptor.
**Option B:** This option is incorrect because clopidogrel is an antiplatelet agent that inhibits ADP receptor P2Y12, not the glycoprotein IIb/IIIa receptor.
**Option C:** This option is incorrect because fondaparinux is an anticoagulant that inhibits factor Xa, not platelet aggregation.

**Clinical Pearl / High-Yield Fact**
Abciximab is often administered in combination with heparin and aspirin to achieve optimal antiplatelet and anticoagulant effects in patients with acute coronary syndromes.

**Correct Answer: C. Abciximab is a monoclonal antibody that selectively inhibits the glycoprotein IIb/IIIa receptor on platelets, preventing platelet aggregation and fibrinogen binding.**